ArticleCNS spectrums2025

Rebuilding the atrophied brain: 6-month nasal esketamine therapy expands key frontal and hippocampal regions and reduces serum neurofilament levels in patients with major depressive disorder. A proof-of-concept study of the depTesk (DEPression treatment with ESKetamine) study.

Ana Rodríguez Lorente et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.